Primary Immune Deficiency Clinic
原发性免疫缺陷诊所
基本信息
- 批准号:10927915
- 负责人:
- 金额:$ 112.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AirAneurysmAortaAreaArteriesArthritisAtherosclerosisAutoimmuneAutoimmunityAwardBiopsyBlood VesselsBone Marrow TransplantationBronchiectasisBronchoscopyCOVID-19 pandemicCOVID-19 vaccineCandidaClinicClinicalClinical ProtocolsClinical ResearchCollaborationsCollectionComplexConnective TissueCoronary arteryDataDefectDentalDermatologyDiagnosisDiffuseDiseaseDominant-Negative MutationEarly DiagnosisEczemaEducationEpithelial CellsEtiologyGastrointestinal HemorrhageGenetic Predisposition to DiseaseGenus staphylococcusGoalsGrantHIF1A geneHIV SeronegativityHematopoietic Stem Cell TransplantationHemorrhageHereditary DiseaseHost DefenseHuman PapillomavirusHypersensitivityIL2RG geneIgEImageImmuneImmune responseImmunityImmunologicsIn VitroIncidenceIndividualInfectionInterferonsJob&aposs SyndromeKaposi SarcomaLaboratoriesLaboratory ResearchLaboratory StudyLiver diseasesLongterm Follow-upLungLung diseasesLung infectionsLupusMalignant NeoplasmsManuscriptsMatrix MetalloproteinasesMendelian disorderMorbidity - disease rateMucinsMutationMyocardial InfarctionNational Heart, Lung, and Blood InstituteNational Institute of Allergy and Infectious DiseaseNational Institute of Arthritis, and Musculoskeletal, and Skin DiseasesNational Institute of Diabetes and Digestive and Kidney DiseasesNatural HistoryOccupationsOperative Surgical ProceduresOsteoporosisPaperPathogenesisPathologicPathway interactionsPatient SelectionPatientsPhenotypePopulationPredispositionProspective StudiesProtocols documentationPublishingResearchRisk FactorsSTAT1 geneSTAT3 geneSafetySignal TransductionSiteSkinSpainSputumSubarachnoid HemorrhageSyndromeSystemThinnessTissuesTrainingTransplantationUnited States National Institutes of HealthVascular DiseasesVasculitisViral Load resultVirusairway epitheliumangiogenesisantimicrobial peptideartery stenosisbench to bedsidebiomedical referral centercalcificationcerebral arteryclinical careclinical phenotypecohortcongenital immunodeficiencycoronavirus diseasecytopeniaimprovedinsightinterestinterleukin-12 receptorloss of functionlupus-likemicrobialmicrobiomemortalityneutrophilnovelpathogenpatient orientedpatient populationresearch studyresponsescoliosisskeletal abnormalityskin disorderskin microbiometransplant centersvaccine responsevascular abnormalityviral DNAwound healing
项目摘要
NIAID and NIH has been a leader in the clinical and laboratory research in STAT3 deficient Hyper IgE (Jobs) syndrome for decades. In 2005, I became the primary clinician and clinical research for our cohort of patients, which has risen to over 130 individuals. Identification of loss of function STAT3 mutations as the genetic etiology in 2007 led to intensification of the research studies. Our goal through intensely studying this patient population and their multi-system clinical phenotype is to understand how STAT3 controls is involved in such diffuse pathways as Candida and Staphylococcal control, allergy, atherosclerosis, osteoporosis and scoliosis, and dental abnormalities. The following are some of our main areas of focus:
Vascular abnormalities and Abnormal Tissue Remodeling (Collaborators: Manfred Boehm, NHLBI, Ahmed Gharib, NIDDK, Chris Nagao, NIAMS, Heidi Kong, NIAMS, Ian Myles, NIAID). Over the last decade we have recognized that tissue remodeling is aberrant in those with dominant negative STAT3 mutations. This is evident in the lung through the persistent pneumatoceles forming after infection, and prolonged air leaks after lung surgery. In the vasculature, middle sized artery aneurysm and tortuosity are common and lead to morbidity and mortality with myocardial infarction, subarachnoid hemorrhage, lung hemorrhage and gastro-intestinal hemorrhage. Since 2006, we have been systematically imaging the coronary arteries and more recently the cerebral arteries to allow for early detection of abnormalities. Through imaging and pathological studies, the vessels were found to have an aberrant response to atherosclerosis with adventitial thinning and aneurysmal widening. Dr. Manfred Boehms lab in NHLBI has been leading the bench research focused on abnormal wound healing with disordered matrix metalloproteinase responses, as well as aberrant angiogenesis related to deficient HIF-1alpha signaling, which has been published. Ongoing studies are focused on analyzing our vascular imaging over the last 15 years for incidence, change, and risk factors, primarily with Dr. Ahmed Gharib. In addition, we are performing repeated skin biopsies to further delineate wound healing, including before and after hematopoietic stem cell transplantation, in collaboration with Drs. Kong, Nagao and Myles.
Pulmonary Clearance, Infection Susceptibility (Collaborators: Kenneth Olivier, UNC, Richard Boucher, UNC). Over the years through managing the DN STAT3 patients through pulmonary infections and exacerbations of bronchiectasis, we have noted that the sputum is frequently very tenacious. Through our prior bench-to-bedside award, and a more recent U01 grant with Dr. Ken Olivier and Dr. Richard Boucher, we are investigating the mucin composition, airway epithelial cell as well as airway immunologic host defenses (such as antimicrobial peptides) through collection of sputum and research bronchoscopies.
Autoimmune/Arthritis Phenotyping (Collaborator: Sarthak Gupta, NIAMS) We have published that a subset of the STAT3 DN HIES patients have autoimmune manifestations, identifying several with lupus or lupus-like disease and autoimmune cytopenias. With our NIAMS collaborators we found increased interferon signature and neutrophil NET formation. In collaboration with collaborators in Spain, in vitro studies with jak inhibition showing normalization of some of the abnormalities. We are currently preparing a clinical protocol to evaluate the use of Jak inhibition for those with autoimmunity and DN STAT3 mutations.
DOCK8 Deficiency (Collaborators: Helen Su, NIAID; Heidi Kong, NIAMS, Corina Gonzalez, NCI). DOCK8 deficiency was described at NIAID, and we remain a major referral center for these patients, having evaluated over 50 patients. We have a unique ability, therefore, to further define the clinical phenotype, understand the pathogenesis, and improve therapy. Increasingly we are recognizing the vascular abnormalities, with cerebral artery stenosis, and aortic dilation and calcification. Although infections explain some vasculitis, others remain without a microbial diagnosis and treatment and long-term follow-up after hematopoietic stem cell transplant (HSCT) are ongoing projects. Our relatively large cohort has allowed collaborator Dr. Heidi Kong, dermatology branch NIAMS, to define the skin microbiome in this population, identifying high DNA viral burden even in areas without obvious cutaneous disease, including novel HPV viruses. Ongoing prospective studies are examining the microbiome post HSCT. We are preparing manuscripts covering the clinical and laboratory data for all the patients with DOCK8 deficiency seen at NIH as well as the bone marrow transplant data as we are the largest single site center for transplant in DOCK8 deficiency.
Inborn Errors of Immunity (IEI) beyond STAT3 DN and DOCK8 deficiency: Primarily through the PID clinic, we see patients with varying IEI, and dependent on the disease and its manifestations, we have set up collaborations. Through Dr. Notarangelo's laboratory we are studying the immune defects of STAT1 GOF as well as other combined immune deficiencies. We collaborate with the NCI group studying Kaposi sarcoma to identify underlying IEI in patients with HIV negative Kaposi sarcoma. We collaborate with the NCI IEI transplant group to consider hematopoietic stem cell transplant, including for patients with IL-12R/IFNg defects STAT3 DN, DOCK8 deficiency RAG deficiency, and leaky IL2RG. We collaborate with the NIAMS dermatology microbiome team to better understand pathogen susceptibility.
With the COVID-19 pandemic, we have been interested in not only how our primary immune deficiency patients have responded to COVID illness, but also to the safety and efficacy of the COVID19 vaccine in this population. We previously published an initial paper examining the vaccine response in our cohort and ongoing studies are underway.
NIAID和NIH一直是STAT3缺乏性高IgE(Job)综合征的临床和实验室研究的领导者。 2005年,我成为了我们的一系列患者的主要临床医生和临床研究,该研究已增加到130多人。识别功能STAT3突变丧失为2007年的遗传病因,导致研究的加剧。通过深入研究该患者人群及其多系统临床表型,我们的目标是了解STAT3控制如何参与诸如念珠菌和葡萄球菌控制,过敏,动脉粥样硬化,骨质疏松症和脊柱侧弯以及牙齿异常等弥漫途径。以下是我们的主要重点领域:
血管异常和异常组织重塑(合作者:Manfred Boehm,Nhlbi,Ahmed Gharib,Niddk,Chris Nagao,Niams,Heidi Kong,Niams,Niams,Niams,Ian Myles,Niaid)。在过去的十年中,我们认识到组织重塑在具有主要负STAT3突变的人中是异常的。在肺部通过感染后形成的持续性肺结核,在肺部手术后长时间泄漏,这是显而易见的。在脉管系统中,中大小的动脉瘤和曲折性很常见,并导致心肌梗塞,蛛网膜下腔出血,肺出血和胃肠道出血的发病率和死亡率。自2006年以来,我们一直在系统地对冠状动脉进行成像,最近的大脑动脉允许早期发现异常。通过成像和病理研究,发现血管对动脉粥样硬化有异常的反应,并且增强性动脉瘤。 NHLBI的Manfred Boehms Lab博士一直在领导基准研究,该研究重点介绍了异常的伤口愈合,其基质基质金属蛋白酶反应以及与缺乏HIF-1Alpha信号相关的异常血管生成,该信号已发表。正在进行的研究重点是在过去15年中分析我们的血管成像,主要与艾哈迈德·盖里布(Ahmed Gharib)博士分析发病率,变化和危险因素。 此外,我们正在与DRS合作进行重复的皮肤活检,以进一步描绘造血干细胞移植之前和之后的伤口愈合。 Kong,Nagao和Myles。
肺部清除,感染易感性(合作者:肯尼斯·奥利维尔(Kenneth Olivier),UNC,理查德·布歇(Richard Boucher),UNC)。多年来,通过通过肺部感染和支气管扩张病加重来管理DN STAT3患者,我们注意到痰液经常非常顽强。通过我们先前的基准奖,以及与Ken Olivier博士和Richard Boucher博士的最新U01赠款,我们正在研究粘蛋白成分,气道上皮细胞以及气道免疫宿主防御措施(例如抗菌肽),通过收集Sputum和Research Bronchoscopies。
自身免疫性/关节炎表型(合作者:Sarthak Gupta,NIAMS)我们已经发表了STAT3 DN HIES患者的一部分具有自身免疫性表现,并确定了几种患有狼疮或狼疮性疾病和自身免疫性胞质的疾病。在我们的NIAMS合作者中,我们发现干扰素签名和中性粒细胞网的形成增加。 与西班牙的合作者合作,体外研究与JAK抑制作用,显示了某些异常的标准化。 我们目前正在准备一项临床方案,以评估对自身免疫性和DN STAT3突变的JAK抑制的使用。
Dock8缺乏症(合作者:Helen Su,Niaid; Heidi Kong,Niams,Corina Gonzalez,NCI)。 NIAID描述了Dock8缺乏症,我们仍然是这些患者的主要转诊中心,对50多名患者进行了评估。因此,我们具有进一步定义临床表型,了解发病机理并改善治疗的独特能力。我们越来越多地认识到血管异常,脑动脉狭窄以及主动脉膨胀和钙化。尽管感染解释了一些血管炎,但其他人仍未进行微生物诊断和治疗,以及造血干细胞移植(HSCT)后的长期随访正在进行。 我们相对较大的队列允许合作者Heidi Kong博士Dermatology Branch Niams定义该人群中的皮肤微生物组,即使在没有明显的皮肤疾病(包括新型HPV病毒)的地区,也可以确定高DNA病毒负担。正在进行的前瞻性研究正在研究HSCT后的微生物组。 我们正在准备涵盖所有在NIH上看到的DOCK8缺乏症患者以及骨髓移植数据的临床和实验室数据,因为我们是Dock8缺乏症中最大的移植单位中心。
STAT3 DN和DOCK8缺乏症以外的先天免疫力(IEI)(IEI):主要是通过PID诊所,我们看到IEI不同的患者,并且依赖于疾病及其表现,我们已经建立了协作。 通过Notarangelo博士的实验室,我们正在研究STAT1 GOF以及其他合并免疫缺陷的免疫缺陷。 我们与研究Kaposi肉瘤的NCI组合作,以识别HIV阴性Kaposi肉瘤患者的基本IEI。 我们与NCI IEI移植组合作考虑造血干细胞移植,包括针对IL-12R/IFNG缺陷的患者STAT3 DN,DOCK8缺乏RAG缺乏和渗漏IL2RG。 我们与NIAMS皮肤病学微生物组团队合作,以更好地了解病原体的敏感性。
借助Covid-19的大流行,我们不仅对我们的原发性免疫缺陷患者如何应对COVID疾病,而且对该人群中Covid19疫苗的安全性和功效感兴趣。 我们先前发表了一篇初始论文,研究了我们队列中的疫苗反应,并且正在进行的研究正在进行中。
项目成果
期刊论文数量(29)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
STAT3 modulates reprogramming efficiency of human somatic cells; insights from autosomal dominant Hyper IgE syndrome caused by STAT3 mutations.
- DOI:10.1242/bio.052662
- 发表时间:2020-09-10
- 期刊:
- 影响因子:2.4
- 作者:Yu Z;Dmitrieva NI;Walts AD;Jin H;Liu Y;Ping X;Ferrante EA;Qiu L;Holland SM;Freeman AF;Chen G;Boehm M
- 通讯作者:Boehm M
Lupus-like autoimmunity and increased interferon response in patients with STAT3-deficient hyper-IgE syndrome.
- DOI:10.1016/j.jaci.2020.07.024
- 发表时间:2021-03
- 期刊:
- 影响因子:0
- 作者:Goel RR;Nakabo S;Dizon BLP;Urban A;Waldman M;Howard L;Darnell D;Buhaya M;Carmona-Rivera C;Hasni S;Kaplan MJ;Freeman AF;Gupta S
- 通讯作者:Gupta S
Warts and DADA2: a Mere Coincidence?
- DOI:10.1007/s10875-018-0565-0
- 发表时间:2018-11-01
- 期刊:
- 影响因子:9.1
- 作者:Arts, Katrijn;Bergerson, Jenna R. E.;Meyts, Isabelle
- 通讯作者:Meyts, Isabelle
STAT3 Hyper-IgE Syndrome-an Update and Unanswered Questions.
- DOI:10.1007/s10875-021-01051-1
- 发表时间:2021-07
- 期刊:
- 影响因子:9.1
- 作者:Tsilifis C;Freeman AF;Gennery AR
- 通讯作者:Gennery AR
Malignancy in STAT3 Deficient Hyper IgE Syndrome.
STAT3 缺陷型高 IgE 综合征中的恶性肿瘤。
- DOI:10.1007/s10875-021-01197-y
- 发表时间:2022
- 期刊:
- 影响因子:9.1
- 作者:Urban,Amanda;NCILymphomaPhysiciansConsortium;Pittaluga,Stefania;CaseWesternPhysiciansConsortium;Freeman,AlexandraF
- 通讯作者:Freeman,AlexandraF
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexandra Freeman其他文献
Alexandra Freeman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexandra Freeman', 18)}}的其他基金
相似国自然基金
基于几何形态与生物力学分析预测腹主动脉瘤腔内治疗术后锚定区相关不良事件
- 批准号:82300542
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
核因子КB受体活化因子配体在腹主动脉瘤形成中的作用及机制研究
- 批准号:82370486
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
SOX9调控线粒体-内质网细胞器互作参与血管平滑肌细胞衰老与腹主动脉瘤的机制研究
- 批准号:82301780
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
PP2A调控内皮细胞EndMT促进腹主动脉瘤发展的机制研究
- 批准号:82370488
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
丙酮酸脱氢酶激酶4调控血管平滑肌细胞表型转换在主动脉瘤/夹层中的作用及机制
- 批准号:82370485
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
NIMBLE - an artificial intelligence-based early warning system for bladder cancer
NIMBLE——基于人工智能的膀胱癌早期预警系统
- 批准号:
486937 - 财政年份:2023
- 资助金额:
$ 112.93万 - 项目类别:
Miscellaneous Programs
2/2 IMPRroving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)
2/2 血管疾病的改善结果 - 主动脉夹层 (IMPROVE-AD)
- 批准号:
10663555 - 财政年份:2023
- 资助金额:
$ 112.93万 - 项目类别:
Towards Personalized Prosthetic Graft Replacement for Genetically Triggered Thoracic Aortic Aneurysms
针对基因触发的胸主动脉瘤的个性化假体移植
- 批准号:
10753115 - 财政年份:2023
- 资助金额:
$ 112.93万 - 项目类别:
2023 Elastin, Elastic Fibers and Microfibrils Gordon Research Conference and Gordon Research Seminar
2023年弹性蛋白、弹性纤维和微纤维戈登研究会议和戈登研究研讨会
- 批准号:
10754079 - 财政年份:2023
- 资助金额:
$ 112.93万 - 项目类别:
Vascular Smooth Muscle Protein Quality Control and Aortic Aneurysm Formation
血管平滑肌蛋白质量控制与主动脉瘤形成
- 批准号:
10714562 - 财政年份:2023
- 资助金额:
$ 112.93万 - 项目类别: